secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0000950170-25-044549
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.
- ACR-368 BM+ endometrial cancer: 35% confirmed ORR, 80% DCR in 20 heavily pretreated patients (median 2 prior lines).
- In BM+ patients refractory to last prior therapy (ORR 0%), ACR-368 achieved 33% ORR and 75% DCR.
- Company deprioritized ovarian and bladder cancers; shifting resources to ACR-368 in endometrial cancer and ACR-2316.
- ACR-2316 Phase 1: cleared DL2 without safety concerns; initial clinical activity observed in a patient at DL3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/0000950170-25-044549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/acrv-20250325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer